Johnson & Johnson Shares Outstanding 2011-2025 | JNJ
Johnson & Johnson shares outstanding history from 2011 to 2025. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
- Johnson & Johnson shares outstanding for the quarter ending September 30, 2025 were 2.429B, a 0.03% increase year-over-year.
- Johnson & Johnson 2024 shares outstanding were 2.429B, a 5.12% decline from 2023.
- Johnson & Johnson 2023 shares outstanding were 2.56B, a 3.89% decline from 2022.
- Johnson & Johnson 2022 shares outstanding were 2.664B, a 0.38% decline from 2021.
|
Johnson & Johnson Annual Shares Outstanding (Millions of Shares) |
|
|---|---|
| 2024 | 2,429 |
| 2023 | 2,560 |
| 2022 | 2,664 |
| 2021 | 2,674 |
| 2020 | 2,671 |
| 2019 | 2,684 |
| 2018 | 2,729 |
| 2017 | 2,745 |
| 2016 | 2,789 |
| 2015 | 2,813 |
| 2014 | 2,864 |
| 2013 | 2,877 |
| 2012 | 2,813 |
| 2011 | 2,775 |
| 2010 | 2,789 |
|
Johnson & Johnson Quarterly Shares Outstanding (Millions of Shares) |
|
|---|---|
| 2025-09-30 | 2,429 |
| 2025-06-30 | 2,419 |
| 2025-03-31 | 2,424 |
| 2024-12-31 | 2,429 |
| 2024-09-30 | 2,428 |
| 2024-06-30 | 2,422 |
| 2024-03-31 | 2,430 |
| 2023-12-31 | 2,560 |
| 2023-09-30 | 2,550 |
| 2023-06-30 | 2,626 |
| 2023-03-31 | 2,606 |
| 2022-12-31 | 2,664 |
| 2022-09-30 | 2,661 |
| 2022-06-30 | 2,668 |
| 2022-03-31 | 2,667 |
| 2021-12-31 | 2,674 |
| 2021-09-30 | 2,675 |
| 2021-06-30 | 2,672 |
| 2021-03-31 | 2,673 |
| 2020-12-31 | 2,671 |
| 2020-09-30 | 2,669 |
| 2020-06-30 | 2,666 |
| 2020-03-31 | 2,671 |
| 2019-12-31 | 2,684 |
| 2019-09-30 | 2,670 |
| 2019-06-30 | 2,692 |
| 2019-03-31 | 2,699 |
| 2018-12-31 | 2,729 |
| 2018-09-30 | 2,728 |
| 2018-06-30 | 2,721 |
| 2018-03-31 | 2,732 |
| 2017-12-31 | 2,745 |
| 2017-09-30 | 2,738 |
| 2017-06-30 | 2,742 |
| 2017-03-31 | 2,755 |
| 2016-12-31 | 2,789 |
| 2016-09-30 | 2,785 |
| 2016-06-30 | 2,794 |
| 2016-03-31 | 2,804 |
| 2015-12-31 | 2,813 |
| 2015-09-30 | 2,807 |
| 2015-06-30 | 2,812 |
| 2015-03-31 | 2,826 |
| 2014-12-31 | 2,864 |
| 2014-09-30 | 2,864 |
| 2014-06-30 | 2,874 |
| 2014-03-31 | 2,875 |
| 2013-12-31 | 2,877 |
| 2013-09-30 | 2,881 |
| 2013-06-30 | 2,893 |
| 2013-03-31 | 2,859 |
| 2012-12-31 | 2,813 |
| 2012-09-30 | 2,818 |
| 2012-06-30 | 2,798 |
| 2012-03-31 | 2,775 |
| 2011-12-31 | 2,775 |
| 2011-09-30 | 2,778 |
| 2011-06-30 | 2,781 |
| 2011-03-31 | 2,773 |
| 2010-12-31 | 2,789 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $472.053B | $88.821B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $969.283B | 46.62 |
| AbbVie (ABBV) | United States | $410.669B | 24.59 |
| Roche Holding AG (RHHBY) | Switzerland | $286.026B | 0.00 |
| Novartis AG (NVS) | Switzerland | $277.276B | 14.70 |
| Merck (MRK) | United States | $230.630B | 10.74 |
| Novo Nordisk (NVO) | Denmark | $215.481B | 12.63 |
| Pfizer (PFE) | United States | $142.484B | 7.83 |
| Sanofi (SNY) | France | $128.030B | 12.30 |
| Bayer (BAYRY) | Germany | $32.184B | 5.65 |
| Innoviva (INVA) | United States | $1.664B | 8.33 |